Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) with a Medtronic Investigational Enhanced-Advanced Hybrid Closed Loop System (e-AHCL)

• DOI: 10.2337/figshare.25111319.v1
• Publication Date: 2024-02-21T16:38:21Z
• Authors: Cheng Yi Yuan; Yee W. Kong; Tess Amoore; Katrin Brown; Benyamin Grosman; Alicia Jenkins; Hannah Jones; Natalie Kurtz; Melissa H. Lee; Richard MacIsaac; Emma Netzer; Barbora Paldus; Lesley Robinson; Anirban Roy; Catriona M. Sims; Steven Trawley; Sara Vogrin; David N. O’Neal

<p dir="ltr">Objective: To determine feasibility and compare acceptance of an investigational Medtronic enhanced-Advanced Hybrid Closed Loop (e-AHCL) system in type 1 diabetes adults with earlier iterations.</p><p dir="ltr">Research Design Methods: Non-randomised three-stage (each twelve weeks) exploratory study comparing e-AHCL (Bluetooth®-enabled MiniMed™ 780G insulin pump automatic data upload [780G] incorporating updated algorithm; calibration-free all-in-one disposable sensor; seven-day infusion set) preceded by a Run-in (Non-Bluetooth® [670G V4.0 pump] requiring manual upload; Guardian Sensor 3 [GS3] calibration; three-day set), Stage (780G; GS3; infusion-set) 2 4; set). Treatment satisfaction was assessed Diabetes Technology Questionnaire (DTQ)-current (primary outcome) other validated treatment tools glucose outcomes continuous monitoring (CGM) metrics.</p><p dir="ltr">Results: Twenty-one 22 (11 women) participants (baseline HbA1c 6.7% / 50mmol/mol) completed the study. DTQ-current scores favored (123.1 [17.8]) vs. (101.6 [24.2]), (110.6 [20.8]) (both p<0.001) but did not differ from (119.4 [16.0]; p=0.271). Medication System Rating short-form for ‘Convenience Efficacy’ over all stages. Percent time range (TIR) 70-180mg/dL greater (+2.9% +3.6% respectively; both p<0.001). <70mg/dL were significantly lower than Run-in, ( -0.9%, -0.6%, -0.5% p<0.01). </p><p dir="ltr">Conclusions: feasible. User increased compared HCL iterations without compromising control.</p>